{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:50:19Z","timestamp":1779915019522,"version":"3.53.1"},"update-to":[{"DOI":"10.1002\/14651858.cd007815","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T00:00:00Z","timestamp":1369958400000}}],"reference-count":118,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007815.pub2","type":"journal-article","created":{"date-parts":[[2013,5,28]],"date-time":"2013-05-28T13:45:17Z","timestamp":1369748717000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Quetiapine versus typical antipsychotic medications for schizophrenia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Sirijit","family":"Suttajit","sequence":"first","affiliation":[{"name":"Chiang Mai University; Department of Psychiatry, Faculty of Medicine; Chiang Mai Thailand 50200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manit","family":"Srisurapanont","sequence":"additional","affiliation":[{"name":"Chiang Mai University; Department of Psychiatry, Faculty of Medicine; Chiang Mai Thailand 50200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health, Sir Colin Campbell Building, University of Nottingham Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siritree","family":"Suttajit","sequence":"additional","affiliation":[{"name":"Chiang Mai University; Faculty of Pharmacy; Chiang Mai Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benchalak","family":"Maneeton","sequence":"additional","affiliation":[{"name":"Chiang Mai University; Department of Psychiatry, Faculty of Medicine; Chiang Mai Thailand 50200"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narong","family":"Maneeton","sequence":"additional","affiliation":[{"name":"Chiang Mai University; Department of Psychiatry, Faculty of Medicine; Chiang Mai Thailand 50200"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,31]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD007815.pub2-BIB0001|cit1","first-page":"285","article-title":"A comparative study of efficacy and safety of seroquel versus chlorpromazine in the treatment of schizophrenia","volume":"31","author":"Ai","year":"2007","journal-title":"Heilongjiang Medical Journal"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0002|cit2","unstructured":"AstraZeneca A Multicenter, double-blind, randomized, comparison of quetiapine (SEROQUEL\u00ae) and chlorpromazine in the treatment of subjects with treatment-resistant schizophrenia http:\/\/www.clinicalstudyresults.org\/ 2005"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0003|cit3","first-page":"151","article-title":"A random chlorpromazine-controlled study of the effects of quetiapine on cognition in schizophrenia","volume":"17","author":"Bai","year":"2005","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"36","key":"10.1002\/14651858.CD007815.pub2-BIB0004|cit4","first-page":"63","article-title":"Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia","volume":"9","author":"Cao","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation [Zhongguo Lin Chuang Kang Fu]"},{"issue":"4","key":"10.1002\/14651858.CD007815.pub2-BIB0005|cit5","first-page":"193","article-title":"Multi-center, double blind control study of domestic manufactured quetiapine on schizophrenia","volume":"34","author":"Chen","year":"2001","journal-title":"Chinese Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0006|cit6","first-page":"149","article-title":"A double-blind and double-dummy comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"11","author":"Zhao","year":"2002","journal-title":"Chinese New Drugs Journal"},{"issue":"5","key":"10.1002\/14651858.CD007815.pub2-BIB0007|cit7","first-page":"319","article-title":"Quetiapine treatment in schizophrenia curative effect and quality of life","volume":"17","author":"Chen","year":"2007","journal-title":"Linchuang Jingshen Yixue Zazhi"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0008|cit8","first-page":"75","article-title":"Control studies on efficacy of quetiapine vs chlorpromazine in first - episode schizophrenics","volume":"9","author":"Guo","year":"2003","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD007815.pub2-BIB0009|cit9","first-page":"583","article-title":"Effect of quetiapine and chlorpromazine on cognitive function in first-episode schizophrenic","volume":"15","author":"Guo","year":"2007","journal-title":"Chinese Journal of Health Psychology"},{"issue":"10","key":"10.1002\/14651858.CD007815.pub2-BIB0010|cit10","first-page":"680","article-title":"A comparative study of quetiapine and chlorpromazine in the treatment of patients with schizophrenia","volume":"22","author":"He","year":"2003","journal-title":"Herald of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007815.pub2-BIB0011|cit11","first-page":"467","article-title":"The effects of antipsychotics on serum prolactin in the first-episode schizophrenia patients","volume":"18","author":"Hu","year":"2003","journal-title":"West China Journal of Pharmaceutical Sciences"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0012|cit12","first-page":"73","article-title":"Comparative study between the quality of life and its curative effect in schizophrenic patients treated with quetiapine or chlorpromazine","volume":"17","author":"Ji","year":"2004","journal-title":"Sichuan Mental Health"},{"issue":"6","key":"10.1002\/14651858.CD007815.pub2-BIB0013|cit13","first-page":"352","article-title":"A random and controlled study of quetiapine and chlorpromazine in patients with schizophrenia","volume":"16","author":"Jiang","year":"2006","journal-title":"Linchuang Jingshen Yixue Zazhi"},{"issue":"19","key":"10.1002\/14651858.CD007815.pub2-BIB0014|cit14","first-page":"56","article-title":"Seroquel and chlorpromazine in treatment of schizophrenia: a random, controlled trial","volume":"16","author":"Jin","year":"2007","journal-title":"China Pharmaceuticals"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0015|cit15","first-page":"135","article-title":"A study of quetiapine and chlorpromazine on the effects and quality of life in the treatment of schizophrenia","volume":"7488","author":"Li","year":"2003","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","article-title":"A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"96","author":"Peuskens","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"17","key":"10.1002\/14651858.CD007815.pub2-BIB0017|cit17","first-page":"723","article-title":"Comparison of efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"19","author":"Mei","year":"2007","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"6","key":"10.1002\/14651858.CD007815.pub2-BIB0018|cit18","first-page":"606","article-title":"A randomized double - blind controlled study on the efficacy of quetiapine and chlorpromazine in treatment of schizophrenia","volume":"21","author":"Peng","year":"2006","journal-title":"West China Journal of Pharmaceutical Sciences"},{"issue":"9","key":"10.1002\/14651858.CD007815.pub2-BIB0019|cit19","first-page":"682","article-title":"Comparative study on the effect of seroquel and chlorpromazine on schizophrenia","volume":"17","author":"Tian","year":"2006","journal-title":"China Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0020|cit20","first-page":"288","article-title":"Comparison of efficacy and safety of quetiapine and larctigal in the treatment of schizophrenia","volume":"13","author":"Wang","year":"2004","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0021|cit21","first-page":"83","article-title":"Efficacy of quetiapine in the treatment of female patients with schizophrenia","volume":"17","author":"Wang","year":"2005","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0022|cit22","first-page":"149","article-title":"A double-blind study of domestic quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"15","author":"Zhang","year":"2002","journal-title":"Shandong Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0023|cit23","first-page":"163","article-title":"A comparison study on efficacy and safety of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"19","author":"Zhang","year":"2003","journal-title":"Chinese Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0024|cit24","first-page":"103","article-title":"Comparative study of influence of quetiapine on life quality in schizophrenic patients","volume":"15","author":"Zhong","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007815.pub2-BIB0025|cit25","first-page":"699, 700-1","article-title":"Comparison between quetiapine and chlorpromazine in cognitive function of schizophrenic patients","volume":"17","author":"Zhou","year":"2003","journal-title":"Chinese Mental Health Journal"},{"issue":"11","key":"10.1002\/14651858.CD007815.pub2-BIB0026|cit26","first-page":"657","article-title":"A comparative study on quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"16","author":"Zhou","year":"2004","journal-title":"Medical Journal of Chinese Peoples Health"},{"issue":"12","key":"10.1002\/14651858.CD007815.pub2-BIB0027|cit27","first-page":"51","article-title":"Study on quetiapine and chlorpromazine in treatment of schizophrenia","volume":"15","author":"Zou","year":"2006","journal-title":"China Pharmaceuticals"},{"issue":"4","key":"10.1002\/14651858.CD007815.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wnf.0000172993.89879.0f","article-title":"Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia","volume":"28","author":"Conely","year":"2005","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \"seroquel\" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0188-4409(02)00403-4","article-title":"Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol","volume":"33","author":"Atmaca","year":"2002","journal-title":"Archives of Medical Research"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0033291799001476","article-title":"A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia","volume":"30","author":"Copolov","year":"2000","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200015030-00001","article-title":"A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated partial response to conventional antipsychotic treatment","volume":"15","author":"Emsley","year":"2000","journal-title":"International Clinical Psychophramacology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","article-title":"A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia","volume":"65","author":"Emsley","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"American Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD007815.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial","volume":"78","author":"Fleischhacker","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"16","key":"10.1002\/14651858.CD007815.pub2-BIB0037|cit37","first-page":"96","article-title":"Comparison of compliance and effectiveness of quetiapine and haloperidol in the treatment of schizophrenia","volume":"13","author":"Huang","year":"2007","journal-title":"International Medicine and Health Guidance News"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Murasaki M Koyama T Yamauchi T Yagi MG Ushijima S Kamijima K Clinical evaluation of quetiapine in schizophrenia - efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany Hamburg, Germany 1999","DOI":"10.2165\/00128413-199912110-00012"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0040|cit40","first-page":"137","article-title":"Neuropsychological change in patients with schizophrenia after treatment with schizophrenia after treatment with quetiapine or haloperidol","volume":"26","author":"Purdon","year":"2001","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0041|cit41","unstructured":"Taneli B Alptekin K Bilici M Birsoz S Eker E Cosar B Comparison of efficacy and tolerability of quetiapine and haloperidol in acute exacerbation of chronic or subchronic schizophrenia Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic Prague, Czech Republic 2003"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0920-9964(01)00268-7","article-title":"Does cognitive function improve with quetiapine in comparison to haloperidol?","volume":"53","author":"Velligan","year":"2002","journal-title":"Schizophrenia Research"},{"issue":"11","key":"10.1002\/14651858.CD007815.pub2-BIB0043|cit43","first-page":"434-5, 7","article-title":"A clinical analysis between quetiapine and haloperidol in the treatment of schizophrenia","volume":"19","author":"Zou","year":"2007","journal-title":"Medical Journal of Chinese People's Health"},{"issue":"5","key":"10.1002\/14651858.CD007815.pub2-BIB0044|cit44","first-page":"321","article-title":"Controlled observation on senile schizophrenics treated with quetiapine and perphenazine","volume":"17","author":"Chen","year":"2007","journal-title":"Linchuang Jingshen Yixue Zazhi"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1209\u201323","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/ajp.2007.164.3.428","article-title":"Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: Findings from the NIMH CATIE study","volume":"164","author":"Swartz","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD007815.pub2-BIB0048|cit48","first-page":"522","article-title":"The contrast investigation between quetiapine and perphenazlne in the treatment of first episode of schizophrenia in children","volume":"2","author":"Yi","year":"2006","journal-title":"Journal of the North Sichuan Medical College"},{"issue":"1,2","key":"10.1002\/14651858.CD007815.pub2-BIB0049|cit49","first-page":"221","article-title":"Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment resistant schizophrenia","volume":"49","author":"Buckley","year":"2001","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0050|cit50","first-page":"78","article-title":"Control observation of quetiapine vs chlorpromazine in schizophrenia","volume":"9","author":"Cheng","year":"2003","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD007815.pub2-BIB0051|cit51","first-page":"398","article-title":"A clinical comparative analysis of quetiapine and chlorpromazine in treatment of schizophrenia","volume":"16","author":"Du","year":"2004","journal-title":"Medical Journal of Chinese Peoples Health"},{"issue":"5","key":"10.1002\/14651858.CD007815.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4088\/JCP.v66n0515","article-title":"Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder","volume":"66","author":"Glick","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Goldstein J Emsley R Raniwalla J Bailey P Jones M Efficacy and tolerability of quetiapine compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA Boca Raton, Florida, USA. 1999","DOI":"10.1016\/S0924-977X(99)80283-1"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0054|cit54","unstructured":"Grecu G Grecu GM Pop M Clinical effectiveness of atypical vs typical antipsychotics in treatment of schizophrenia patients Proceedings of the 19th European College of Neuropsychopharmacology Congress; 2006 Sep 16-20; Paris, France Paris, France 2006"},{"issue":"5","key":"10.1002\/14651858.CD007815.pub2-BIB0055|cit55","first-page":"257","article-title":"The effect of chlorpromazine and quetiapine on serum lipid and glucose","volume":"16","author":"Guo","year":"2006","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"1,2","key":"10.1002\/14651858.CD007815.pub2-BIB0056|cit56","first-page":"231","article-title":"Efficacy of quetiapine in antipsychotic na\u00efve patients","volume":"49","author":"Hammond","year":"2001","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007815.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?","volume":"16","author":"Kelemen","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007815.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4088\/JCP.v66n0111","article-title":"Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine","volume":"66","author":"Kelly","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","article-title":"A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia","volume":"31","author":"Kelly","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0061|cit61","unstructured":"Kong DL Zhang SQ Shu MQ Effects of quetiapine and chlorpromazine on serum prolactin of schizophrenics Journal of Clinical Psychosomatic Diseases 2003 200 1"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Lee M Meltzer HY Quetiapine is significantly superior to haloperidol and placebo in improving mood in patients with schizophrenia Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany Berlin, Germany 2001","DOI":"10.3109\/15622970009150597"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0063|cit63","first-page":"285","article-title":"Atypical versus typical antipsychotic treatment prognosis in first-episode paranoid schizophrenia based on WCST and dichotic listening scores","volume":"11","author":"Loza","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0064|cit64","unstructured":"Ma ZW Li MX Shi YZ Wang LH Quetipine (35 patients) vs chlorpromazine (34 patients) in treatment of schizophrenia Chinese Journal of New Drugs and Clinical Remedies 2004 273 5"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0065|cit65","first-page":"38","article-title":"Effect of quetiapine on cognition function of patients with first episode schizophrenia","volume":"28","author":"Nai","year":"2007","journal-title":"Journal of Medical Forum"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0066|cit66","first-page":"138","article-title":"A comparative study between quetiapine and haloperidol on the life quality of the patients with schizophrenia","volume":"7489","author":"Qiu","year":"2003","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0067|cit67","unstructured":"Reveley M Seroquel Outcome Study (SOS): a multicentre double-blind randomised trial to compare the effects of seroquel and chlorpromazine on treatment outcome of schizophrenic patients National Research Register 2001"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0068|cit68","unstructured":"Richardson CM Kelly DL Gold JM McMahon R Yu Y Conley RR Risperidone vs quetiapine vs fluphenazine in treatment - resistant schizophrenia: neuropsychological outcome Schizophrenia Bulletin 2005 501 2"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0069|cit69","unstructured":"Sharma T A multi-centre, double-blind, randomised trial to compare the effects of \"seroquel\" and haloperidol in schizophrenic patients with a history of partial response to antipsychotic treatment National Research Register 2001"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0070|cit70","first-page":"97","article-title":"A comparative study of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"9","author":"Zhang","year":"2007","journal-title":"Modern Medicine Journal of China"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0072|cit72","first-page":"53","article-title":"Scale for the assessment of negative symptoms (SANS)","volume":"7","author":"Andreasen","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0073|cit73","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0074|cit74","volume-title":"Practice guideline for the treatment of patients with schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007815.pub2-BIB0076|cit76","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0077|cit77","article-title":"Concept of schizophrenia","volume-title":"Kaplan & Sadock's Comprehensive Textbook of Psychiatry","author":"Buchanan","year":"2005"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0080|cit80","first-page":"233","article-title":"The extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0081|cit81","unstructured":"Deeks JJ Issues in the selection of a summary statistic for meta-analyses of binary data Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD007815.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"8746","key":"10.1002\/14651858.CD007815.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007815.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF02244924","article-title":"Seroquel: electrophysiological profile of a potential atypical antipsychotic","volume":"112","author":"Goldstein","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0089|cit89","first-page":"95","article-title":"Preclinical tests that predict clozapine-like atypical antipsychotic actions","volume":"10","author":"Goldstein","year":"1995","journal-title":"Critical Issues in the Treatment of Schizophrenia"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0090|cit90","unstructured":"Goldstein JM Cristoph G Grimm S Liu JW Widzowski D Brecher M Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: Data from the health survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0092|cit92","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0095|cit95","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org 2008","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0096|cit96","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0097|cit97","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.164.2.141","article-title":"The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research","volume":"164","author":"Kerwin","year":"1994","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007815.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006654.pub2","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2-3","key":"10.1002\/14651858.CD007815.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD007815.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0102|cit102","unstructured":"Leucht S Arbter D Engel RR Kissling W Davis JM How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials http:\/\/www.nature.com\/mp\/journal\/vaop\/ncurrent\/full\/4002136a.html 1 19 10.1038\/sj.mp.4002136"},{"issue":"21","key":"10.1002\/14651858.CD007815.pub2-BIB0103|cit103","first-page":"1","article-title":"Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs","volume":"3","author":"Liu-Seifert","year":"2005","journal-title":"BMC Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007815.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02244925","article-title":"Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug","volume":"112","author":"Migler","year":"1993","journal-title":"Psychopharmacology"},{"issue":"15","key":"10.1002\/14651858.CD007815.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement:revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/002076409904500102","article-title":"Application and results of the Manchester Short Assessment of Quality of Life (MANSA)","volume":"45","author":"Priebe","year":"1999","journal-title":"International Journal of Social Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD007815.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244923","article-title":"Seroquel: biochemical profile of a potential atypical antipsychotic","volume":"112","author":"Saller","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"2","key":"10.1002\/14651858.CD007815.pub2-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD007815.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1503\/cmaj.090523","article-title":"A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers","volume":"180","author":"Thorpe","year":"2009","journal-title":"CMAJ : Canadian Medical Association journal (Journal de l'Association Medicale Canadienne)"},{"issue":"5","key":"10.1002\/14651858.CD007815.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD007815.pub2-BIB0117|cit117","unstructured":"Xia J Adams CE Bhagat N Bhagat V Bhoopathi P El-Sayeh H The Leeds Outcomes Stakeholders Survey (LOSS) Study Proceedings of the 15th Cochrane Colloquium; 2007 23-27 October; Sao Paulo 2007"},{"issue":"7","key":"10.1002\/14651858.CD007815.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007815.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T06:23:59Z","timestamp":1742883839000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007815.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,31]]},"references-count":118,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007815.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,31]]}}}